A
Arndt Vogel
Researcher at Hannover Medical School
Publications - 415
Citations - 17655
Arndt Vogel is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 50, co-authored 322 publications receiving 10740 citations. Previous affiliations of Arndt Vogel include Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Fabio Piscaglia,Ari David Baron,Joong-Won Park,Guohong Han,Jacek Jassem,Jean-Frédéric Blanc,Arndt Vogel,Dmitry Komov,T.R. Jeffry Evans,Carlos Lopez,Corina E. Dutcus,Matthew Guo,Kenichi Saito,Silvija Kraljevic,Toshiyuki Tamai,Min Ren,Ann-Lii Cheng +21 more
TL;DR: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma and the safety and tolerability profiles of lenvatinIB were consistent with those previously observed.
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.
M. Reig,Alejandro Forner,Jordi Rimola,Joana Ferrer-Fàbrega,Marta Burrel,Ángeles García-Criado,Robin Katie Kelley,Peter R. Galle,Vincenzo Mazzaferro,Riad Salem,Bruno Sangro,Amit G. Singal,Arndt Vogel,Josep Fuster,C. Ayuso,Jordi Bruix +15 more
TL;DR: In this paper, the authors present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need to further research to gain their incorporation into an evidence-based model for clinicians and researchers.
Journal ArticleDOI
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Vaibhav Sahai,Antoine Hollebecque,Gina M. Vaccaro,Davide Melisi,Raed Al-Rajabi,Andrew Scott Paulson,Mitesh J. Borad,David Gallinson,Adrian Murphy,Do Youn Oh,Efrat Dotan,Daniel V.T. Catenacci,Eric Van Cutsem,Tao Ji,Christine F. Lihou,Hui-Ling Zhen,Luis Féliz,Arndt Vogel +19 more
TL;DR: These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.
Journal ArticleDOI
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister,Dominik Pfister,Nicolás Gonzalo Núñez,Roser Pinyol,Olivier Govaere,Matthias Pinter,Marta Szydlowska,Revant Gupta,Mengjie Qiu,Aleksandra Deczkowska,Assaf Weiner,Florian Müller,Ankit Sinha,Ankit Sinha,Ekaterina Friebel,Thomas Engleitner,Thomas Engleitner,Daniela Lenggenhager,Anja Moncsek,Danijela Heide,Kristin Stirm,Jan Kosla,Eleni Kotsiliti,Valentina Leone,Michael Dudek,Suhail Yousuf,Donato Inverso,Donato Inverso,Indrabahadur Singh,Ana Teijeiro,Florian Castet,Carla Montironi,Philipp K. Haber,Dina Tiniakos,Dina Tiniakos,Pierre Bedossa,Simon Cockell,Ramy Younes,Ramy Younes,Michele Vacca,Fabio Marra,Jörn M. Schattenberg,Michael Allison,Elisabetta Bugianesi,Vlad Ratziu,Tiziana Pressiani,Antonio D'Alessio,Nicola Personeni,Lorenza Rimassa,Ann K. Daly,Bernhard Scheiner,Katharina Pomej,Martha M. Kirstein,Arndt Vogel,Markus Peck-Radosavljevic,F. Hucke,Fabian Finkelmeier,Oliver Waidmann,Jörg Trojan,Kornelius Schulze,Henning Wege,Sandra Koch,Arndt Weinmann,Marco Bueter,Fabian Rössler,Alexander Siebenhüner,Sara De Dosso,Jan-Philipp Mallm,Viktor Umansky,Viktor Umansky,Manfred Jugold,Tom Luedde,Andrea Schietinger,Andrea Schietinger,Peter Schirmacher,Brinda Emu,Hellmut G. Augustin,Hellmut G. Augustin,Adrian T. Billeter,Beat P. Müller-Stich,Hiroto Kikuchi,Dan G. Duda,Fabian Kütting,Dirk Waldschmidt,Matthias P. Ebert,Nuh N. Rahbari,Henrik E. Mei,Axel Schulz,Marc Ringelhan,Nisar P. Malek,Stephan Spahn,Michael Bitzer,Marina Ruiz de Galarreta,Amaia Lujambio,Jean-François Dufour,Thomas U. Marron,Thomas U. Marron,Ahmed Kaseb,Masatoshi Kudo,Yi Hsiang Huang,Yi Hsiang Huang,Nabil Djouder,Katharina Wolter,Lars Zender,Lars Zender,Parice N. Marche,Parice N. Marche,Thomas Decaens,Thomas Decaens,David J. Pinato,Roland Rad,Roland Rad,Joachim C. Mertens,Achim Weber,Kristian Unger,Felix Meissner,Susanne Roth,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Manfred Claassen,Quentin M. Anstee,Ido Amit,Percy A. Knolle,Burkhard Becher,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Mathias Heikenwalder +128 more
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.